Purple Biotech Ltd. amended a USD 200,000,000 shelf registration after selling 691,806 ADSs for approximately USD 2.3 million under its ATM program; it also discontinued CM24 and NT219 and expects an IM1240 IND during 2027.
Read from the first part of this long document5 source passages
The Registration Statement, as amended by this Amendment, contains a base prospectus which covers the offering, issuance and sale by us of up to USD 200,000,000 of ordinary shares, which may be represented by ADSs, preferred shares, warrants, overallotment purchase rights, subscription rights, units and/or capital notes (collectively, the “Shelf Securities”).In accordance with the terms of the Sales Agreement, we may offer and sell ADSs from time to time through Wainwright, acting as our agent. We have sold an aggregate of 691,806 ADSs for gross proceeds of approximately USD 2.3 million pursuant to the Sales Agreement under our registration statement on Form F-3 (File No. 333-268710), of which 607,982 ADSs for gross proceeds of approximately USD 1.9 million were sold after May 22, 2026, the date such registration statement expired, in reliance on Rule 415(a)(5)(ii) under the Securities Act of 1933, as amended (the “Securities Act”).We have since discontinued development of CM24 and NT219, and in October 2026, our subsidiaries initiated the process to terminate each of the NT219 license agreement and the CM24 license agreement.Subject to obtaining sufficient additional funding, we expect to submit an IND application to the FDA for IM1240 during 2027 and to initiate a first-in-human study thereafter.This Pre-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form F-3 (File No. 333-296088) (the “Registration Statement”) of Purple Biotech Ltd. (the “Company”) is being filed to include updated disclosures since the Registration Statement was originally filed on May 20, 2026.Open the document at this passage
Purple Biotech Ltd. appointed Isaac Israel Interim Chief Executive Officer effective October 5, 2026, pending a permanent appointment; Gil Efron will transition to Executive Director, Head of Corporate Development while remaining a director.
